Physician profile
Adam Jay Scheiner
NPI 1396737201
$3,419.22
in general payments reported to CMS, 2019-2025
12 companies · $683 in 2025
The $683 reported for 2025 was more than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $517 · 2021: $273 · 2022: $60.05 · 2023: $453 · 2024: $821 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,957.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $718.72 | 2019-2023 | |
| Revance Therapeutics, INC. | $645.21 | 2024-2025 | Daxxify |
| Galderma Laboratories, L.P. | $593.26 | 2019-2025 | Dysport |
| Abbvie INC. | $504.10 | 2023-2025 | Botox |
| Allergan, INC. | $424.45 | 2019-2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $143.32 | 2020 | |
| Horizon Therapeutics Plc | $124.99 | 2020 | |
| Bausch & Lomb Americas INC. | $121.39 | 2025 | Miebo, Xiidra |
| Dompe US, INC. | $83.86 | 2025 | Oxervate |
| Alcon Vision LLC | $23.36 | 2019 | |
| Aclaris Therapeutics, INC. | $21.06 | 2019 | |
| Aerie Pharmaceuticals, INC. | $15.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Scheiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.